Infliximab biosimilar CT-P13 for inflammatory bowel disease

被引：5
|
作者：
Bonovas, Stefanos [1 ,2 ]
Peyrin-Biroulet, Laurent [3 ,4 ]
Danese, Silvio [1 ,2 ]
机构：
[1] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20090 Milan, Italy
[2] Humanitas Clin & Res Ctr, IBD Ctr, Milan, Italy
[3] Univ Lorraine, Univ Hosp Nancy, Dept Hepatogastroenterol, Vandoeuvre Les Nancy, France
[4] Univ Lorraine, Univ Hosp Nancy, INSERM, U954, Vandoeuvre Les Nancy, France
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2018年 / 3卷 / 06期
关键词：
DOUBLE-BLIND; SAFETY; INNOVATOR; EFFICACY; COHORT; TRIAL;
D O I：
10.1016/S2468-1253(18)30116-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：373 / 375
页数：4
相关论文
共 50 条
  • [1] CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease
    Albshesh, Ahmad
    Ben-Horin, Shomron
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 971 - 978
  • [2] A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
    Farkas, Klaudia
    Molnar, Tamas
    [J]. IMMUNOTHERAPY, 2018, 10 (02) : 107 - 117
  • [3] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [4] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [5] Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13
    Parigi, Tommaso Lorenzo
    D'Amico, Ferdinando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 37 - 46
  • [6] Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment
    Gompertz, M.
    Alfaro, I.
    Ricart, E.
    Lopez, A.
    Panes, J.
    Gallego, M.
    Barastegui, R.
    Giner, A.
    Vara, A.
    Masamunt, M.
    Ordas, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S427 - S428
  • [7] Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
    Jahnsen, Jorgen
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 322 - 329
  • [8] Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Kadivar, Mohammad
    Molin, Daniel
    Angelison, Leif
    Hammarlund, Per
    Olin, Marie
    Torp, Jorgen
    Grip, Olof
    Nilson, Stefan
    Hertervig, Erik
    Lillienau, Jan
    Marsal, Jan
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
  • [9] Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease
    Elosua Gonzalez, Alfonso
    Sanz Segura, Patricia
    Oyon Lara, Daniel
    Lopez Garcia, Santiago
    Arroyo Villarino, Maria Teresa
    Alcala Escriche, Maria Jose
    Ollero Domenche, Leticia
    Rodriguez Gutierrez, Cristina
    Nantes Castillejo, Oscar
    [J]. MEDICINA CLINICA, 2020, 154 (12): : 475 - 480
  • [10] Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease
    Maria Huguet, Jose
    Cortes, Xavier
    Maia Bosca-Watts, Marta
    Aguas, Marian
    Maroto, Nuria
    Marti, Lidia
    Amoros, Cirilo
    Maria Paredes, Jose
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (36) : 11285 - 11299
12345